Phase II trial of trimetrexate in patients with stage III and IV non-small-cell lung cancer Journal Article
| Authors: | Kris, M. G.; D'Acquisto, R. W.; Gralla, R. J.; Burke, M. T.; Marks, L. D.; Fanucchi, M. P.; Heelan, R. T. |
| Article Title: | Phase II trial of trimetrexate in patients with stage III and IV non-small-cell lung cancer |
| Abstract: | Trimetrexate is a nonclassical antifolate with greater preclinical antitumor activity than methotrexate. Fourteen patients with stage III or IV non-small-cell lung cancer who had not previously received chemotherapy were given trimetrexate (12 mg/m2 intravenously daily for 5 days) every 3 weeks. No major objective responses were observed (95% confidence limits: 0-20%). Ten of the 14 patients had grade 2 or greater toxicity, with 50% experiencing grade 2 or greater leukopenia and/or thrombocytopenia. Nausea, vomiting, rash, mucositis, diarrhea, and serum glutamic-oxaloacetic transaminase (SGOT) elevations were also seen. At the dosage and schedule of trimetrexate used, no responses occurred in this population of patients with non-small-cell lung cancer. With the low response rate and the observed degree of myelosuppression, trimetrexate appears to have limited utility in this disease. |
| Keywords: | adult; clinical article; aged; phase 2 clinical trial; bone marrow suppression; leukopenia; lung non small cell cancer; mucosa inflammation; thrombocytopenia; intravenous drug administration; trimetrexate; human; male; female |
| Journal Title: | American Journal of Clinical Oncology |
| Volume: | 12 |
| Issue: | 1 |
| ISSN: | 0277-3732 |
| Publisher: | Lippincott Williams & Wilkins |
| Date Published: | 1989-02-01 |
| Start Page: | 24 |
| End Page: | 26 |
| Language: | English |
| DOI: | 10.1097/00000421-198902000-00006 |
| PUBMED: | 2536213 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Export Date: 14 April 2020 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work